Study backs NMP48 marker over PSA (prostate specific antigen) for prostate cancer
This article was originally published in Clinica
Early study results have indicated that Matritech's blood test for prostate cancer may be more specific than the widely used PSA (prostate specific antigen) test for ruling out the disease.
You may also be interested in...
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.